Chagas disease, a neglected tropical diseasecaused by Trypanosoma cruzi, remainsa significant global healthconcern.1 Despite existing treatments,there is an urgent need for new, more effective drugs.2 Recent research has focused on exploring novel targets,including enzymes involved in ergosterol biosynthesis3 (CYP51), protein degradation4 (cruzain), triosephosphate isomerase energy metabolism5 (TPI), and nucleotide synthesis6 (DHODH). Here, TPI1 is linked to Chagas disease.